Plain English Summary
Current plain English summary as of 01/07/2020:
Background and study aims
Preeclampsia is a serious pregnancy complication which can threaten the life and well-being of both the mother and the baby. There is a simple method of identifying women who are at very high risk of developing preeclampsia. During a hospital visit at 35 – 36 weeks of pregnancy, information is recorded about maternal characteristics (such as age, weight, and race) and medical history (such as chronic hypertension, diabetes, and if previous pregnancies were complicated by preeclampsia). A measurement is also taken of the woman’s blood pressure and a blood sample is taken to measure levels of proteins that are associated with preeclampsia. A computer program then calculates the woman’s chance of developing preeclampsia. Those women found to be at high risk are invited to participate in this study, which investigates whether the use of a drug called pravastatin can prevent the development of preeclampsia.
Who can participate?
Pregnant women age over 18 who are at high risk of preeclampsia
What does the study involve?
Participants are randomly allocated to take one capsule per day of either pravastatin or a matching placebo (dummy drug). Participants are asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women have a follow-up visit 6 weeks after delivery. Incidence of preeclampsia with delivery is assessed by examination of patient hospital records and patient interviews.
What are the possible benefits and risks of participating?
The benefit for women taking part in the study is that they will know whether they are at high risk for developing preeclampsia or not. Those found to be at high risk will have more close monitoring of their blood pressure and the growth of their baby and they will benefit from such closer monitoring irrespective of whether they are allocated to the pravastatin or placebo group. If the study finds that pravastatin is useful in preventing preeclampsia, the women will benefit from such treatment in a future pregnancy, because women that get preeclampsia in one pregnancy are at much higher risk of developing preeclampsia in a future pregnancy. Extensive studies have reported that statins are not harmful to the fetus.
Where is the study run from?
1. King's College Hospital (UK)
2. The Royal London Hospital (UK)
3. Medway Maritime Hospital (UK)
4. North Middlesex Hospital (UK)
5. Homerton University Hospital (UK)
6. Southend University Hospital (UK)
7. Virgen de la Arrixaca (Spain)
8. Hospital Universitario La Paz (Spain)
9. Hospital de Torrejon (Spain)
10. CHU Brugmann (Belgium)
When is the study starting and how long is it expected to run for?
December 2016 to November 2020 (updated 08/10/2019, previously: March 2020)
Who is funding the study?
Fetal Medicine Foundation (UK)
Who is the main contact?
Prof. Kypros Nicolaides
eliza.tylki@nhs.net
Previous plain English summary :
Background and study aims
Preeclampsia is a serious pregnancy complication which can threaten the life and well-being of both the mother and the baby. There is a simple method of identifying women who are at very high risk of developing preeclampsia. During a hospital visit at 35 – 36 weeks at pregnancy information is recorded about maternal characteristics (such as, age, weight and race) and medical history (such as, chronic hypertension, diabetes, previous pregnancies complicated by preeclampsia). A measurement is also taken of the woman’s blood pressure (MAP), an ultrasound machine measures the blood flow from the mother to the placenta (UTPI), and a blood sample is taken to measure the level of a protein produced by the placenta (PLGF). A computer program then calculates the woman’s chance of developing preeclampsia. Those women found to be at high risk are invited to participate in this study, which investigates whether the use of a drug called pravastatin can prevent the development of preeclampsia.
Who can participate?
Pregnant women age over 18 who are at high risk of preeclampsia
What does the study involve?
Participants are randomly allocated to take one capsule per day of either pravastatin or a matching placebo (dummy drug). Participants are asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women have a follow-up visit 6 weeks after delivery. Incidence of preeclampsia with delivery is assessed by examination of patient hospital records and patient interviews.
What are the possible benefits and risks of participating?
The benefit for women taking part in the study is that they will know whether they are at high risk for developing preeclampsia or not. Those found to be at high risk will have more close monitoring of their blood pressure and the growth of their baby and they will benefit from such closer monitoring irrespective of whether they are allocated to the pravastatin or placebo group. If the study finds that pravastatin is useful in preventing preeclampsia, the women will benefit from such treatment in a future pregnancy, because women that get preeclampsia in one pregnancy are at much higher risk of developing preeclampsia in a future pregnancy. Extensive studies have reported that statins are not harmful to the fetus.
Where is the study run from?
1. King's College Hospital (UK)
2. The Royal London Hospital (UK)
3. Medway Maritime Hospital (UK)
4. North Middlesex Hospital (UK)
5. Homerton University Hospital (UK)
6. Southend University Hospital (UK)
7. Spitalul Filantropia Bucharest (Romania)
8. Virgen de la Arrixaca (Spain)
9. Hospital Universitario La Paz (Spain)
10. Hospital de Torrejon (Spain)
11. Ospedale Maggiore Policlinico (Italy)
12. CHU Brugmann (Belgium)
When is the study starting and how long is it expected to run for?
December 2016 to November 2020 (updated 08/10/2019, previously: March 2020)
Who is funding the study?
Fetal Medicine Foundation (UK)
Who is the main contact?
Prof. Kypros Nicolaides
eliza.tylki@nhs.net
Study website
Contact information
Type
Scientific
Contact name
Prof Kypros Nicolaides
ORCID ID
Contact details
Fetal Medicine Research Institute
King’s College Hospital
London
SE5 8BB
United Kingdom
+44 (0)2032998256
eliza.tylki@nhs.net
Additional identifiers
EudraCT/CTIS number
2016-005206-19
IRAS number
ClinicalTrials.gov number
Protocol/serial number
33496
Study information
Scientific title
Randomised controlled trial with pravastatin versus placebo for prevention of preeclampsia
Acronym
STATIN
Study hypothesis
Preeclampsia (PE) is an important cause of maternal and perinatal mortality and morbidity. A major challenge in modern obstetrics is early identification of pregnancies at high risk of PE and undertaking the necessary measures to reduce the incidence of the disease. Extensive research has demonstrated that the development of PE can be predicted by a combination of maternal demographic characteristics and medical and obstetric history and biophysical markers including uterine artery pulsatility index (PI) and mean arterial pressure (MAP) and biochemical markers including maternal serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT-1). Although screening at 11-13, 20-24 and 30-34 weeks is effective at identifying pregnancies at high-risk of developing PE at < 37 weeks’ gestation (preterm-PE) the performance of screening for term-PE is poor. Large multicentre studies have shown that although adverse outcomes for the mother and baby are more serious with preterm-PE the contribution of term-PE to such adverse outcomes is at least as high because the condition is much more common (incidence 0.5-0.7% for preterm-PE and 2-2.5% for term-PE). For example, in half of the maternal deaths from hypertensive disorders of pregnancy in the UK and Ireland at 2009-2014, the death occurred at > 37 weeks gestation. Effective screening for term-PE can be achieved by a combination of maternal factors, MAP, PLGF and sFLT-1 at the time of a routine ultrasound scan to monitor fetal growth at 35-37 weeks of gestation. The objective of this study is to examine if the prophylactic use of pravastatin from 35-37 weeks’ gestation in women at increased risk for term-PE can reduce the incidence and severity of the disease.
Ethics approval(s)
London - London Bridge Research Ethics Committee, 20/02/2017, ref: 17/LO/0130
Study design
Randomised; Both; Design type: Prevention, Drug, Cohort study
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Study setting(s)
Hospital
Study type
Prevention
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet: Anca Ciobanu: anca.ciobanu@nhs.net; Moritz Döbert: moritz.dobert@nhs.net
Condition
Pre-eclampsia
Intervention
Current interventions as of 01/07/2020:
This is a double-blind randomised placebo-controlled trial for which the eligible participants will be identified by a screening study. In the participating centres in Spain, Belgium and the UK, all women attending for their routine hospital visit in pregnancy at 35+0-36+6 weeks’ gestation will be screened to identify a high-risk group for development of Preeclampsia (PE). In this visit the trialists will record maternal characteristics and medical history, measure the maternal MAP and serum PLGF and sFLT-1 and on the basis of these results estimate the risk for term-PE. Women that are screened positive for term-PE will be invited to participate in the randomised trial of pravastatin. Participants will take one capsule per day of either pravastatin 20mg or matching placebo. Participants will be asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women will have a follow-up visit 6 weeks after delivery.
Previous interventions:
This is a double-blind randomised placebo-controlled trial for which the eligible participants will be identified by a screening study. In the participating centres in Spain, Italy, Belgium, Romania and the UK, all women attending for their routine hospital visit in pregnancy at 35+0-36+6 weeks’ gestation will be screened to identify a high-risk group for development of PE. In this visit the trialists will record maternal characteristics and medical history, measure the maternal MAP and serum PLGF and sFLT-1 and on the basis of these results estimate the risk for term-PE. Women that are screened positive for term-PE will be invited to participate in the randomised trial of pravastatin. Participants will take one capsule per day of either pravastatin 20mg or matching placebo. Participants will be asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women will have a follow-up visit 6 weeks after delivery.
Intervention type
Drug
Pharmaceutical study type(s)
Phase
Not Applicable
Drug/device/biological/vaccine name(s)
Pravastatin
Primary outcome measure
Incidence of PE with delivery, assessed by examination of patient hospital records and patient interviews
Secondary outcome measures
Current secondary outcome measures as of 01/07/2020:
Assessed by examination of patient hospital records and patient interviews:
1. Adverse outcome of pregnancy at any gestation
2. Adverse outcome of pregnancy at ≥37 weeks’ gestation
3. Stillbirth or neonatal death
4. Neonatal morbidity
5. Neonatal therapy
6. Incidence of low birth weight
7. sFLT-1 and PLGF value at 1 and 3 weeks after the onset of treatment
8. Pravastatin safety assessment during pregnancy: at 1 and 2 weeks after the onset of treatment, at term, 6 weeks after delivery
Previous secondary outcome measures:
Assessed by examination of patient hospital records and patient interviews:
1. Adverse outcome of pregnancy at any gestation
2. Adverse outcome of pregnancy at >37 weeks’ gestation
3. Stillbirth or neonatal death
4. Neonatal morbidity
5. Neonatal therapy
6. Incidence of low birth weight
7. sFLT-1 and PLGF value at 1 and 3 weeks after the onset of treatment
8. Pravastatin safety assessment during pregnancy: at 1 and 2 weeks after the onset of treatment, at term, 6 weeks after delivery
Overall study start date
20/12/2016
Overall study end date
30/11/2020
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Current participant inclusion criteria as of 01/07/2020:
1. Pregnant women without established preeclampsia
2. Singleton pregnancy
3. Live fetus at 35+0-36+6 weeks’ gestation
4. Informed and written consent
5. Age ≥18 years
6. Not unconscious or very ill
7. No serious mental illness
8. No learning difficulties
9. Fluent in local language or translation by interpreter
Inclusion criteria for participant selection for RCT:
1. Same as for screening
2. Identified at screening as being at high-risk for term-PE by the algorithm combining maternal history and characteristics, MAP, PLGF and sFLT-1
3. Informed and written consent
4. No planned delivery within 7 days of planned randomisation date;
5. No major fetal abnormality;
6. No statin use within 28 days prior to randomisation;
7. None of the following contraindications for statin therapy:
7.1. Hypersensitivity to pravastatin or any component of the product
7.2. Lactose intolerance
7.3. Current or previous cancer
7.4. Previous solid organ transplant
7.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
7.6. Chronic renal disease/insufficiency with baseline serum creatinine ≥1.5mg/dL
7.7. History of myopathy or rhabdomyolysis
7.8. ALT and/or AST levels ≥ 2 x the upper limit of normal
7.9. Creatine kinase levels ≥ 5 x the upper limit of normal
7.10. Concurrent and chronic (>6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, therapeutic doses of niacin for hyperlipidaemia (low doses found in dietary/nutritional supplements such as pregnancy supplements may be used), protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
7.11. Participating in another intervention study that influences the outcomes of this study
Previous participant inclusion criteria:
1. Pregnant women without established preeclampsia
2. Singleton pregnancy
3. Live fetus at 35+0-36+6 weeks’ gestation
4. Informed and written consent
5. Age >18 years
6. Not unconscious or very ill
7. No serious mental illness
8. No learning difficulties
9. Fluent in local language or translation by interpreter
10. No major fetal abnormality
11. No statin use within 28 days prior to randomisation
12. None of the following contraindications for statin therapy:
12.1. Hypersensitivity to pravastatin or any component of the product
12.2. Lactose intolerance
12.3. Current or previous cancer
12.4. Previous solid organ transplant
12.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
12.6. Chronic renal disease/insufficiency with baseline serum creatinine >1.5mg/dL
12.7. History of myopathy or rhabdomyolysis
12.8. ALT and/or AST levels ≥ 2 x the upper limit of normal
12.9. Creatine kinase levels ≥ 5 x the upper limit of normal
12.10. Concurrent and chronic (>6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, niacin, protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
12.11. Participating in another intervention study that influences the outcomes of this study
Inclusion criteria for participant selection for RCT:
1. Same as for screening
2. Identified at screening as being at high-risk for term-PE by the algorithm combining maternal history and characteristics, MAP, PLGF and sFLT-1
3. Informed and written consent
Participant type(s)
Patient
Age group
Adult
Lower age limit
18 Years
Sex
Female
Target number of participants
Planned Sample Size: 1120; UK Sample Size: 750
Total final enrolment
1129
Participant exclusion criteria
Current participant exclusion criteria as of 01/07/2020:
For the randomised trial, same as for screening, but in addition:
1. Major fetal abnormality
2. Women with established PE
3. Statin use within 28 days prior to randomisation
4. Women with contraindications for statin therapy:
4.1. Hypersensitivity to pravastatin or any component of the product
4.2. Lactose intolerance
4.3. Current or previous cancer
4.4. Previous solid organ transplant
4.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
4.6. Chronic renal disease/insufficiency with baseline serum creatinine ≥ 1.5mg/dL
4.7. History of myopathy or rhabdomyolysis
4.8. ALT and/or AST levels > = 2 x the upper limit of normal
4.9. Creatine kinase levels > = 5 x the upper limit of normal
4.10. Concurrent and chronic (>6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, therapeutic doses of niacin for hyperlipidaemia (low doses found in dietary/nutritional supplements such as pregnancy supplements may be used), protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
5. Participating in another intervention study that influences the outcomes of this study
Previous participant exclusion criteria:
For the randomised trial, same as for screening, but in addition:
1. Major fetal abnormality
2. Women with established PE
3. Statin use within 28 days prior to randomisation
4. Women with contraindications for statin therapy:
4.1. Hypersensitivity to pravastatin or any component of the product
4.2. Lactose intolerance
4.3. Current or previous cancer
4.4. Previous solid organ transplant
4.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
4.6. Chronic renal disease/insufficiency with baseline serum creatinine > 1.5mg/dL
4.7. History of myopathy or rhabdomyolysis
4.8. ALT and/or AST levels > = 2 x the upper limit of normal
4.9. Creatine kinase levels > = 5 x the upper limit of normal
4.10. Concurrent and chronic (> 6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, niacin, protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
5. Participating in another intervention study that influences the outcomes of this study
Recruitment start date
16/08/2018
Recruitment end date
30/11/2019
Locations
Countries of recruitment
Belgium, England, Spain, United Kingdom
Study participating centre
King‘s College Hospital
Windsor Walk 16-20
London
SE5 8BB
United Kingdom
Study participating centre
The Royal London Hospital
Whitechapel Rd
Whitechapel
London
E1 1BB
United Kingdom
Study participating centre
Medway Maritime Hospital
Windmill Road
Gillingham
ME7 5NY
United Kingdom
Study participating centre
North Middlesex Hospital
Sterling Way
London
N18 1QX
United Kingdom
Study participating centre
Homerton University Hospital
Homerton Row
London
E9 6SR
United Kingdom
Study participating centre
Southend University Hospital
Prittlewell Chase
Westcliff-on-Sea
SS0 0RY
United Kingdom
Study participating centre
Virgen de la Arrixaca
Ctra. Madrid-Cartagena, s/n, El Palmar
Murcia
30120
Spain
Study participating centre
Hospital Universitario La Paz
Paseo de la Castellana, 261
Madrid
28046
Spain
Study participating centre
Hospital de Torrejon
Calle Mateo Inurria, s/n, Torrejón de Ardoz
Madrid
28850
Spain
Study participating centre
CHU Brugmann
Place A.Van Gehuchten 4
Brussels
1020
Belgium
Sponsor information
Organisation
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
Sponsor details
Sponsor responsibilities for Trial Management are delegated to the Fetal Medicine Foundation (FMF) for sites in the UK and Belgium by the regulator
primary sponsor.
C / Luis Fontes Pagán No. 9
1st floor
Murcia
30003
Spain
Sponsor type
Hospital/treatment centre
Website
ROR
Organisation
King's College Hospital
Sponsor details
c/o Prof Kypros Nicolaides
Fetal Medicine Research Institute
London
SE5 8BB
England
United Kingdom
+44 (0)2032998256
eliza.tylki@nhs.net
Sponsor type
Hospital/treatment centre
Website
https://www.kch.nhs.uk/patientsvisitors/getting-to-kings
ROR
Funders
Funder type
Charity
Funder name
Fetal Medicine Foundation
Alternative name(s)
FMF
Funding Body Type
private sector organisation
Funding Body Subtype
Trusts, charities, foundations (both public and private)
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Planned publication in high-impact peer reviewed journals.
Intention to publish date
30/11/2021
Individual participant data (IPD) sharing plan
The data sharing plans for the current study are unknown and will be made available at a later date.
IPD sharing plan summary
Data sharing statement to be made available at a later date
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | 01/06/2021 | 25/06/2021 | Yes | No | |
HRA research summary | 28/06/2023 | No | No | ||
Other publications | 22/06/2023 | 10/05/2024 | Yes | No |